Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Status: | Recruiting |
---|---|
Conditions: | Cancer, Brain Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 8/23/2018 |
Start Date: | May 2013 |
End Date: | May 2020 |
Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes.
Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas,
known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b
(mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue.
This study tests the hypothesis that in primary glioma samples mir-10b expression patterns
will serve as a prognostic and diagnostic marker. This study will also characterize the
phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the
critical function of anti-mir-10b in blocking established glioblastoma growth, the
investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b
treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients
diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b
expression levels. Patient survival, as well as tumor grade and genotypic variations will be
correlated to mir-10b expression levels.
Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas,
known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b
(mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue.
This study tests the hypothesis that in primary glioma samples mir-10b expression patterns
will serve as a prognostic and diagnostic marker. This study will also characterize the
phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the
critical function of anti-mir-10b in blocking established glioblastoma growth, the
investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b
treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients
diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b
expression levels. Patient survival, as well as tumor grade and genotypic variations will be
correlated to mir-10b expression levels.
Inclusion/Exclusion Criteria:
- 18 years of age
- Brain tumor(s) to be resected for clinical reasons.
- Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III
or IV.
- Adequate tissue available for processing as determined by Pathology.
- Adequate decision making ability to review, discuss and sign a consent form to allow
their tumor samples to be used for future human brain tumor biology laboratory
research. Determination of capacity to consent is made by one of the co-investigators
based on clinical assessment.
- Patients opting for the standard treatment regimen for their disease as well as
ongoing clinical trials will be are eligible to participate in this study. Standard
care for newly-diagnosed glioblastomas typically consists of surgical resection
followed by radiotherapy with concomitant temozolomide, followed by adjuvant
temozolomide chemotherapy.
We found this trial at
4
sites
University of Vermont The University of Vermont combines faculty-student relationships most commonly found in a...
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
Boston, Massachusetts 02111
(617) 636-5000
Phone: 617-636-2883
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
Boston, Massachusetts 02114
617-724-5200
Phone: 617-643-4395
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
Lebanon, New Hampshire 03756
(603) 650-5000
Principal Investigator: Arti B Gaur, PhD
Phone: 800-639-6918
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials